<code id='74D7F10F74'></code><style id='74D7F10F74'></style>
      • <acronym id='74D7F10F74'></acronym>
      <center id='74D7F10F74'><center id='74D7F10F74'><tfoot id='74D7F10F74'></tfoot></center><abbr id='74D7F10F74'><dir id='74D7F10F74'><tfoot id='74D7F10F74'></tfoot><noframes id='74D7F10F74'>
      • <optgroup id='74D7F10F74'><strike id='74D7F10F74'><sup id='74D7F10F74'></sup></strike><code id='74D7F10F74'></code></optgroup>
        5. <b id='74D7F10F74'><label id='74D7F10F74'><select id='74D7F10F74'><dt id='74D7F10F74'><span id='74D7F10F74'></span></dt></select></label></b><u id='74D7F10F74'></u>
          <i id='74D7F10F74'><strike id='74D7F10F74'><tt id='74D7F10F74'><pre id='74D7F10F74'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / entertainment / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-27 18:25:25 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：8
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Pfizer is about to make a big push in cancer. Will investors listen?
                                
                            
          Next article：  
                                      
                                          As demand for Covid shots wanes, Moderna seeks its next success
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles